YarcData Aligns With Selventa to Help Pharmaceutical Companies Deliver Personalized Medicine

YarcData Aligns With Selventa to Help Pharmaceutical Companies Deliver 
Personalized Medicine 
PLEASANTON, CA -- (Marketwired) -- 10/15/13 --  YarcData, a Cray
(NASDAQ: CRAY) company committed to providing a big data solutions
for real-time data discovery, today announced a collaborative effort
with Selventa, a leading provider of systems diagnostics for
personalized medicine. Selventa will have access to YarcData's big
data analytics appliance, Urika(R), to help pharmaceutical
organizations better target drugs, condense the time needed for new
drug discoveries and accelerate market delivery.  
"With 50 percent of drugs ineffective or worse, there is an immediate
opportunity to better match treatments to individuals based on their
biomarker profiles. Using this insight, pharmaceutical companies can
create a larger number of targeted products that optimally benefit
patients," said Dave de Graaf, President and CEO, Selventa.  
"Big data and the intellectual properties derived from it have an
immense potential to drive personalized medicine. This, in turn, will
lead to an increase in knowledge and our requirements for scalable,
flexible solutions that can deliver results in a fraction of the time
than the traditional databases. In searching for a graph database
solution, nothing compared to YarcData's ability to pull all the data
into one platform and one memory space to achieve the real-time speed
and scalability," Dr. Graaf concluded. 
The YarcData Urika platform is a purpose-built, real-time appliance
for automated data discovery that provides graph-optimized hardware
and a graph database optimized for the underlying hardware enabling
applications to interact with the appliance. Although it can be
provisioned and managed by IT as any other Linux server, Urika is a
highly scalable, real-time accelerated data discovery platform that
augments existing systems, bringing data silos together to support ad
hoc queries, pattern-based searches, inferencing and deduction.
Because graph databases are more flexible than traditional systems,
value can be extracted almost immediately, without waiting for months
to build the ontology and load all of the data.  
"Selventa's solution running on Urika will help pharmaceutical
companies do what they have been trying to do on the
ir own -- build
databases that enable new drug discoveries and speed time to market,"
said Dave Anstey, Global Segment Leader for Life Sciences at
YarcData. "We are seeing customers dramatically shorten their
hypothesis validation cycle."  
The combined YarcData and Selventa solution will provide the
opportunity for pharmaceutical companies to explore data discoveries
across disease areas. Traditional databases are usually partitioned
by disease area in order to limit the size of the database and make
searching more manageable. Because data loaded into Urika does not
need to be partitioned, the solution will enable analysis to be
performed across larger or combined data sets, making it possible to
find previously unknown relationships between genes and proteins,
treatments and disease mechanisms, human and animal biology, diseased
tissue and blood, as well as identification of biomarkers
representative of predictive and prognostic indications.  
About Selventa
 Selventa is pioneering the development of Systems
Diagnostics (SysDx(TM)). This novel approach to diagnostic
development harnesses a comprehensive range of complex, biological
information (genomic, epigenomic, transcriptomic, proteomic,
metabolomic, electronic medical records) to generate a clinically
relevant dashboard that physicians, patients and researchers can use
to make an optimal treatment decision or stratify patient
SysDx tests are enabled by Selventa's "Big Data" analytics engine
that integrates, processes, and analyzes the molecular information
from thousands of patients to identify biomarkers linked to
disease-driving mechanisms. SysDx tests are differentiated by their
ability to capture a holistic picture of a patient's disease and
drug-response profile. This is in contrast to MDx tests that are
limited by their focus on a particular class of biological analytes
(e.g. genomics-only tests). This superior predictive and prognostic
value is required in the diagnosis of complex multi-factorial
diseases such as autoimmune disease and cancer. For more information,
visit www.selventa.com. 
About the Urika(TM) Appliance
 Urika is a purpose-built big data
appliance for real-time data discovery using graph analytics. The
appliance helps automate the surfacing of unknown relationships and
non-obvious patterns in diverse data sets without the need for
pre-modeling, partitioning or knowing all the questions in advance.
Urika includes graph-optimized hardware that provides up to 512
terabytes of global shared memory; massively-multithreaded graph
processors supporting 128 threads/processor; highly scalable I/O with
data ingest rates of up to 350 terabytes per hour; and an RDF/SPARQL
database optimized for the underlying hardware. Data-center ready and
standards based, Urika complements an existing data warehouse or
Hadoop cluster and is easy to integrate with existing analytical and
visualization tools.  
About YarcData LLC
 YarcData, a Cray company, delivers a big data
appliance for real-time data discovery, enabling enterprises to gain
game-changing business insights by surfacing unknown relationships
and non-obvious patterns. Adopters include the Swiss National
Supercomputing Centre (CSCS), the Mayo Clinic, Noblis, Oak Ridge
National Laboratory, QinetiQ, Pittsburgh Supercomputing Center and
Sandia National Laboratories, as well as leading government and
intelligence organizations, financial services firms, life sciences
companies, and telecommunications providers. YarcData is based in the
San Francisco Bay Area and more information is at www.yarcdata.com. 
About Cray Inc.
 Global supercomputing leader Cray Inc. (NASDAQ:
CRAY) provides innovative systems and solutions enabling scientists
and engineers in industry, academia and government to meet existing
and future simulation and analytics challenges. Leveraging 40 years
of experience in developing and servicing the world's most advanced
supercomputers, Cray offers a comprehensive portfolio of
supercomputers and Big Data solutions delivering unrivaled
performance, efficiency and scalability. Cray's Adaptive
Supercomputing vision is focused on delivering innovative
next-generation products that integrate diverse processing
technologies into a unified architecture, allowing customers to
surpass today's limitations and meeting the market's continued demand
for realized performance. Go to www.cray.com for more information.  
Cray is a registered trademark of Cray Inc. in the United States and
other countries, and YarcData and Urika are registered trademarks of
Cray Inc. Other product and service names mentioned herein are the
trademarks of their respective owners. 
YarcData Media:
Tamarie Johnson
TNT Communication
Diane H. Song, Ph.D. 
615/547-5421, x235
Cray Investors:
Paul Hiemstra
Press spacebar to pause and continue. Press esc to stop.